Bristol Myers trial revisions shake confidence in new class of fibrosis drugs

Data ReadoutnegativeadmilparantNegative

AI Analysis

Summary

Bristol Myers Squibb's admilparant, a fibrosis drug, experienced trial revisions following reports of liver-related safety events including a patient death during testing, though causality remains unclear.

Clinical Trial Data

Outcome Details

Limited number of liver-related safety events, including a patient death, observed in trial testing

Importance:7/10

Sentiment:

-0.80

safety_eventliver_toxicitypatient_deathtrial_revisionfibrosisdrug_development

Related Companies

$BMY

Read the original article

Published by BioPharma Dive on September 30, 2026 4:22 PM

Read Original